The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training.
Objective. To assess the ability of mental health professionals to use the 4-item Negative Symptom Assessment instrument, derived from the Negative Symptom Assessment-16, to rapidly determine the severity of negative symptoms of schizophrenia.Design. Open participation.Setting. Medical education conferences.Participants. Attendees at two international psychiatry conferences.Measurements. Participants read a brief set of the 4-item Negative Symptom Assessment instructions and viewed a videotape of a patient with schizophrenia. Using the 1 to 6 4-item Negative Symptom Assessment severity rating scale, they rated four negative symptom items and the overall global negative symptoms. These ratings were compared with a consensus rating determination using frequency distributions and Chi-square tests for the proportion of participant ratings that were within one point of the expert rating.Results. More than 400 medical professionals (293 physicians, 50% with a European practice, and 55% who reported past utilization of schizophrenia ratings scales) participated. Between 82.1 and 91.1 percent of the 4-items and the global rating determinations by the participants were within one rating point of the consensus expert ratings. The differences between the percentage of participant rating scores that were within one point versus the percentage that were greater than one point different from those by the consensus experts was significant (p<0.0001). Participants rating of negative symptoms using the 4-item Negative Symptom Assessment did not generally differ among the geographic regions of practice, the professional credentialing, or their familiarity with the use of schizophrenia symptom rating instruments.Conclusion. These findings suggest that clinicians from a variety of geographic practices can, after brief training, use the 4-item Negative Symptom Assessment effectively to rapidly assess negative symptoms in patients with schizophrenia.
Alphs
Larry
L
Dr. Alphs is from Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey (at the time this research was conducted, Dr. Alphs was employed at Pfizer Global R&D, Ann Arbor, Michigan).
Morlock
Robert
R
Coon
Cheryl
C
van Willigenburg
Arjen
A
Panagides
John
J
Psychopharmacol Bull. 1989;25(2):159-63
2602512
J Psychiatr Res. 1993 Jul-Sep;27(3):253-8
7905033
J Clin Psychiatry. 2005 Sep;66(9):1122-9
16187769
Schizophr Res. 1993 Mar;9(1):25-8
8461268
Clin Schizophr Relat Psychoses. 2011 Jul;5(2):87-94
21693432
Psychiatry Res. 1994 May;52(2):173-9
7972573
Br J Psychiatry Suppl. 1989 Nov;(7):49-58
2695141
Curr Med Res Opin. 2005 Dec;21(12):2017-28
16368053
Schizophr Bull. 1987;13(2):261-76
3616518